

## Oxidative Macrocyclizations for the Vancomycin Antibiotics. Unexpected Transannular Effects in the Thallium(III)-Mediated M(2-4) Macrocylic Ring Closure


David A. Evans,\* Christopher J. Dinsmore,<sup>1a</sup> and Andrew M. Ratz<sup>1b</sup>

Department of Chemistry & Chemical Biology, Harvard University, Cambridge, MA 02138, USA

**Abstract:** The course of the Tl(III)-mediated intramolecular oxidative macrocyclization of phenolic residues to provide the M(2-4) diarylether ring of the vancomycin antibiotics is remarkably sensitive to transannular effects across the M(4-6) ring, brought about by variations in the degree of ring-6 chlorination as well as the conformational bias imparted by the distal M(5-7) ring. The effect of structure on this reaction is documented.  
 © 1997 Elsevier Science Ltd.


The members of the vancomycin class of glycopeptide antibiotics are important agents for the treatment of severe bacterial infections, particularly those caused by methicillin-resistant *Staphylococcus aureus*, and the basis of their activity has been of interest for some time.<sup>2</sup> The complex poly-macrocyclic architecture inherent in the vancomycin aglycone structures (**1**, **2**) renders them challenging targets for total synthesis, and many studies directed toward this goal have been reported.<sup>3</sup> Our own efforts thus far have resulted in efficient syntheses of the required amino acid constituents,<sup>4</sup> thallium(III)-mediated oxidative cyclizations to form the M(2-4)(4-6)<sup>5</sup> bicyclic diarylether array,<sup>6</sup> vanadium(V)-induced intramolecular biaryl construction to provide the strained M(5-7) ring,<sup>7</sup> and application of the intramolecular S<sub>N</sub>Ar strategy to the M(2-4) ring closure.<sup>8</sup> The successful integration of all of these methods has recently culminated in the synthesis of a M(4-6)(5-7) bicyclic synthon (**3**, **4**),<sup>9a</sup> as well as the first total synthesis of orienticin C aglycone (**2**).<sup>9b</sup> The purpose of this Letter is to report some key observations pertaining to our initial strategy of employing a late-stage thallium(III)-promoted oxidative cyclization to achieve the M(2-4) diarylether ring closure in the total synthesis of **2**. We have found that the oxidative cyclization is unexpectedly sensitive to subtle but important structural features of the substrates.

Scheme 1




In an initial convergent approach toward the synthesis of **2**, the *dehalogenated* M(4-6)(5-7) tetrapeptide fragment **4** was coupled to the tripeptide fragment **5** in anticipation of oxidative macrocyclization to provide the complete aglycone skeleton.<sup>10a</sup> In the key reaction (Scheme 2), oxidation of heptapeptide **6** in analogy to previously optimized conditions (Tl(NO<sub>3</sub>)<sub>3</sub>•3H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 0 °C)<sup>6</sup> cleanly afforded a less polar intermediate<sup>11</sup> which was then reduced *in situ* (CrCl<sub>2</sub>, 0 °C) to provide returned starting material (**6**, 47%) instead of the desired polycyclic product **7**.

The unexpected failure of **6** to undergo the desired biarylether construction prompted an investigation into the role of the structural features which differ from those of previously reported model studies.<sup>6,12</sup> Of these, the absence of ring-6 aryl halogens (substituents which had been present in all of the previous Tl(III)-mediated cyclizations), as well as the presence of the M(5-7) biaryl portion (absent in all previous studies), were thought to be the most likely structural elements contributing to the unfortunate lack of cyclization.




A model study was designed to define the importance of these structural modifications (Scheme 3). The M(4-6) tripeptide fragment **8**, prepared in analogy to earlier work,<sup>6</sup> was dehalogenated and brominated to give **9**. Both macrocycles were coupled with tripeptide **5**, and deprotected to provide the model substrates **10** (dehalogenated) and **11** (ring-6 dichloride) in good yield. As expected, thallium(III) oxidation of **11** ( $\text{Ti}(\text{NO}_3)_3 \cdot 3\text{H}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2/\text{MeOH}$ , 0 °C) provided a less polar intermediate quinol methyl ether, which was reduced *in situ* ( $\text{CrCl}_2$ , 0 °C) to provide the M(2-4)(4-6) bicyclic hexapeptide **12** in 45% yield. When the oxidation-reduction protocol was applied to *dehalogenated* **10**, the only isolated material was **13** (38%), surprisingly derived from M(2-4) cyclization and M(4-6) ring-cleavage.<sup>13</sup> Thus, the presence of chlorine atoms on ring-6 is essential for a successful oxidative M(2-4) cyclization onto a preexisting M(4-6) template.



The mechanistic construct illustrated below (eq 1, 2) provides a reasonable explanation for why chlorination on ring-6 is important to the outcome of the oxidative transformation. In their respective reactions, the model substrates **11** and **10** may be converted to initial ring-4 *ortho*-thallated intermediates which undergo nucleophilic


attack by the ring-2 phenol to produce **A** (eq 1) and **C** (eq 2), respectively. In the next step, the positional selectivity in the attack of ring-4 by methanol (**A**→**B** and **C**→**D**) likely differs for the two substrates, where the regiochemical outcome is directed by steric hindrance from the neighboring chloro-substituents. In the desired reaction path (eq 1), intermediate *para*-quinol methyl ether **B** is reductively aromatized with loss of MeOH to provide bicyclic product **12**, while in the undesired path (eq 2) an *ortho*-quinol methyl ether **D** is reductively cleaved at the M(4-6) oxygen linkage to provide monocyclic compound **13**.



The observation of distinctly different results in the oxidative reactions of heptapeptide **6** and model compound **10**, which differ only in the presence or absence of the M(5-7) biaryl portion, suggest that there might also be conformational issues that play a significant role in dictating the course of the reaction. Whereas **10** cyclized at M(2-4) and then ring-opened at M(4-6), **6** failed to cyclize at all. The difference is perhaps due to an unfavorable constraint within the M(4-6) ring induced by the presence of the M(5-7)-enforced *cis*-amide bond linking residues 5 and 6,<sup>7,9a</sup> a feature which may influence the rate of intramolecular cyclization onto ring-4. It was our hope at this stage that the retarding effect of the conformation within **6** could be overcome by the reinstallation of ring-6 halogens, enabling cyclization in analogy to the successful transformation **11**→**12**.

The heptapeptide test substrate **14** was derived from the union of **3** and **5**.<sup>10b</sup> The usual oxidation-reduction protocol (Scheme 4) required higher temperature and longer reaction time than was necessary in earlier instances (23 °C, 1.5 h). In contrast to the case of dechlorinated **6**, substrate **14** provided a complex mixture of products which included the desired fully-functionalized aglycone derivative **15** (5-10%) along with recovered starting material (10-20%). The important role of the ring-6 chlorines in the transformation is again indicated. In addition, direct comparison of the reaction of **14** to the more successful cyclization of hexapeptide **10** provides further evidence that *systems possessing the M(5-7) biaryl-containing macrocycle suffer from a conformational bias which undermines the efficiency of the M(2-4) oxidative cyclization onto a preexisting M(4-6) template*.

Scheme 4



Based on these results, it appears that thallium(III)-promoted oxidation chemistry at arylglycine-4 for the M(2-4) macrocyclization is remarkably sensitive to transannular effects across the M(4-6) ring, brought about by variations in ring-6 chlorination as well as conformational change imparted by the more distal M(5-7) ring. These

limitations should have considerable impact on the design of synthetic approaches to the vancomycin aglycones, since partial ring-6 chlorination as well as M(5-7) ring installation are necessary components of any strategy. Current synthetic efforts are focused on alternative cyclization sequences in the overall assembly.

**Acknowledgment.** This research has been supported by the National Institutes of Health and Merck. The NIH BRS Shared Instrumentation Grant 1 S10 RR04870 and the NSF (CHE 88-14019) are acknowledged for providing support for NMR facilities.

### References and Notes

- (1) (a) NIH Postdoctoral Fellow; (b) DOD and Division of Organic Chemistry (ACS) predoctoral fellow.
- (2) (a) Atkinson, B. A. in *Antibiotics in Laboratory Medicine*; Lorian, V., Ed.; Williams and Wilkins: Baltimore, **1986**, 995-1162. (b) *Glycopeptide Antibiotics*; Nagarajan, R., Ed.; Marcel Dekker: New York, 1994. (c) Groves, P.; Searle, M. S.; Waltho, J. P.; Williams, D. H. *J. Am. Chem. Soc.* **1995**, *117*, 7958-7964 and references cited therein. (d) Walsh, C. T.; Fisher, S. L.; Park, I-S.; Prahalad, M.; Wu, Z. *Chemistry & Biology*, **1996**, *3*, 21-28, and references cited therein.
- (3) For reviews of synthetic approaches: (a) Evans, D. A.; DeVries, K. M. In *Glycopeptide Antibiotics*; Nagarajan, R., Ed.; Marcel Dekker, Inc.: New York; 1994; pp. 63-103. (b) Rama Rao, A. V.; Gurjar, M. K.; Reddy, K. L.; Rao, A. S. *Chem. Rev.* **1995**, *95*, 2135-2168.
- (4) (a) Evans, D. A.; Britton, T. C.; Ellman, J. A.; Dorow, R. L. *J. Am. Chem. Soc.* **1990**, *112*, 4011-4030. (b) Evans, D. A.; Evrard, D. A.; Rychnovsky, S. D.; Früh, T.; Whittingham, W. G.; DeVries, K. M. *Tetrahedron Lett.* **1992**, *33*, 1189-1192. (c) Evans, D. A.; Weber, A. E. *J. Am. Chem. Soc.* **1987**, *109*, 7151-7157.
- (5) The seven amino acid residues are numbered consecutively, starting from the amino terminus. The M(X-Y) nomenclature refers to the macrocycle containing an oxidative crosslink between aryl groups of residues X and Y. Bicyclic moieties will be identified as M(X-Y)(Y-Z).
- (6) Evans, D. A.; Ellman, J. A.; DeVries, K. M. *J. Am. Chem. Soc.* **1989**, *111*, 8912-8914.
- (7) (a) Evans, D. A.; Dinsmore, C. J.; Evrard, D. A.; DeVries, K. M. *J. Am. Chem. Soc.* **1993**, *115*, 6426-6427. (b) Evans, D. A.; Dinsmore, C. J. *Tetrahedron Lett.* **1993**, *34*, 6029-6032.
- (8) Evans, D. A.; Watson, P. S. *Tetrahedron Lett.* **1995**, *37*, 3251 - 3254.
- (9) (a) Evans, D. A.; Dinsmore, C. J.; Ratz, A. M.; Evrard, D. A.; Barrow, J. C. *J. Am. Chem. Soc.* **1997**, *119*, in press. (b) Evans, D. A.; Barrow, J. C.; Watson, P. S.; Ratz, A. M.; Dinsmore, C. J.; Evrard, D. A.; DeVries, K. M.; Ellman, J. A.; Rychnovsky, S. D.; Lacour, J. *J. Am. Chem. Soc.* **1997**, *119*, in press.
- (10) (a) Fragment **4** was deprotected, brominated, coupled with **5**, and deprotected to provide **6** using the following reactions: i) MeMgBr, THF, 0 °C, 70%; ii) Br<sub>2</sub>, NaOAc, AcOH, 23 °C, 86%; iii) NaBH<sub>4</sub>, EtOH, 0 °C; iv) **5**, EDC, HOBT, THF, 0 °C, 47% two steps; v) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, THF, 0 °C, 81%. (b) For **3**→**14**: i) NaBH<sub>4</sub>, EtOH, 0 °C, 78%; ii) MeMgBr, THF, 0 °C, 93%; iii) Br<sub>2</sub>, NaOAc, AcOH, 23 °C, 97%; iv) **5**, EDC, HOBT, THF, 0 °C, 93%; v) Pd(PPh<sub>3</sub>)<sub>4</sub>, morpholine, THF, 0 °C, 92%.
- (11) We speculate that this unstable intermediate is a spirocyclic oxazoline derived from intramolecular oxidative attack of the ring-3 amide oxygen onto ring-4. The use of isopropanol as solvent resulted in the same intermediate, as judged by tlc on silica gel.
- (12) a) Suzuki, Y.; Nishiyama, S.; Yamamura, S. *Tetrahedron Lett.* **1989**, *30*, 6043-6046. (b) Suzuki, Y.; Nishiyama, S.; Yamamura, S. *Tetrahedron Lett.* **1990**, *31*, 4053-4056. (c) Nakamura, K.; Nishiyama, S.; Yamamura, S. *Tetrahedron Lett.* **1995**, *36*, 8621-8624. (d) Konishi, H.; Okuno, T.; Nishiyama, S.; Yamamura, S.; Koyasu, K.; Terada, Y. *Tetrahedron Lett.* **1996**, *37*, 8791-8794.
- (13) In the reaction of **10**, partial decomposition was alleviated by using more anhydrous conditions [Ti(NO<sub>3</sub>)<sub>3</sub> dried *in vacuo* with P<sub>2</sub>O<sub>5</sub>; 3Å sieves]. Deuterated solvent was employed to assay for epimerization (*d*-incorporation) at the arylglycine-4 α-position *via* quinone methide formation; none was observed.

(Received in USA 24 February 1997; revised 17 March 1997; accepted 18 March 1997)